Advances in disease-modifying therapy of neuromyelitis optica spectrum disorders
10.3760/cma.j.cn113694-20230814-00052
- VernacularTitle:视神经脊髓炎谱系疾病的疾病修饰治疗研究进展
- Author:
Hongyan LI
1
;
Kan WANG
;
Haojun YU
;
Rui RUI
;
Xiaoying YAO
;
Yangtai GUAN
Author Information
1. 上海交通大学医学院附属仁济医院神经内科，上海 200127
- Keywords:
Neuromyelitis optica;
Drug therapy;
Immunosuppressive agents;
Monoclonal antibodies;
Stem cell transplantation
- From:
Chinese Journal of Neurology
2023;56(12):1435-1446
- CountryChina
- Language:Chinese
-
Abstract:
Neuromyelitis optica spectrum disorders (NMOSD) are a group of autoimmune-mediated inflammatory demyelinating diseases of the central nervous system, characterized by optic nerve and spinal cord lesions, with high chance of recurrence and disability. Disease-modifying therapy, including immunosuppressants, monoclonal antibodies, stem cell transplantation etc., is the key to prevent recurrence. This article made a systematic review about the sequential treatment or prognosis of NMOSD by searching for the related articles published on PubMed from 2017 to 2022 to provide recommendations and references for disease-modifying therapy of NMOSD.
